Di Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Di Wu has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Xunming Ji
Capital Medical University
16 shared publications Chuanjie Wu
Department of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China
9 shared publicationsShuaili Xu
Department of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China
9 shared publicationsJiachen He
Department of Neurology, China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing, China
6 shared publicationsJiaqi Guo
Department of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Beijing Institute of Brain Disorders, Capital Medical University, Beijing, China
6 shared publicationsJian Chen
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
5 shared publications
Latest Publications
- 17 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (854) , eady7847
The translational potential of drug-induced hypothermia in acute ischemic stroke
Hypothermia and hypometabolism are important for hibernating animals to survive harsh environmental conditions. Induction of a hypothermic and hypometabolic state is considered an avenue to treat severe diseases, such as ischemic stroke. However, noninvasive and safe methods to achieve a long-lasting hypothermic and hypometabolic state remain limited. Here, we present data from preclinical and clinical studies to explore the feasibility and safety of drug-induced hypothermia by administration of chlorpromazine and promethazine (C+P). In mice, C+P treatment induced hypothermia and suppressed glucose metabolism in the brain. C+P treatment reduced infarct volumes and improved neurological deficit in a mouse middle cerebral artery occlusion model induced by suture insertion. Furthermore, C+P treatment reduced body temperature, suppressed metabolism, and exerted cerebroprotective effects in a rhesus monkey model of stroke. In a double-blind, phase 1 clinical trial (NCT06663631), a total of 32 patients diagnosed with acute ischemic stroke were enrolled, receiving either placebo or increasing doses of C+P treatment: 10, 20, 50, or 100 milligrams. All doses were safe and well tolerated. Only 100 milligrams of C+P resulted in a modest and transient reduction in body temperature. Plasma proteomic profiling revealed a down-regulation of markers associated with aerobic respiration and glucose metabolism. These findings highlight the translational potential of C+P treatment and warrant a larger trial to further investigate safety and efficacy of C+P.
- 17 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (854) , eady7847
The translational potential of drug-induced hypothermia in acute ischemic stroke
Hypothermia and hypometabolism are important for hibernating animals to survive harsh environmental conditions. Induction of a hypothermic and hypometabolic state is considered an avenue to treat severe diseases, such as ischemic stroke. However, noninvasive and safe methods to achieve a long-lasting hypothermic and hypometabolic state remain limited. Here, we present data from preclinical and clinical studies to explore the feasibility and safety of drug-induced hypothermia by administration of chlorpromazine and promethazine (C+P). In mice, C+P treatment induced hypothermia and suppressed glucose metabolism in the brain. C+P treatment reduced infarct volumes and improved neurological deficit in a mouse middle cerebral artery occlusion model induced by suture insertion. Furthermore, C+P treatment reduced body temperature, suppressed metabolism, and exerted cerebroprotective effects in a rhesus monkey model of stroke. In a double-blind, phase 1 clinical trial (NCT06663631), a total of 32 patients diagnosed with acute ischemic stroke were enrolled, receiving either placebo or increasing doses of C+P treatment: 10, 20, 50, or 100 milligrams. All doses were safe and well tolerated. Only 100 milligrams of C+P resulted in a modest and transient reduction in body temperature. Plasma proteomic profiling revealed a down-regulation of markers associated with aerobic respiration and glucose metabolism. These findings highlight the translational potential of C+P treatment and warrant a larger trial to further investigate safety and efficacy of C+P.
- Open Access
- 20 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Efficacy and safety of albumin combined with endovascular therapy in the treatment of patients with acute ischemic stroke: a randomized clinical trial
The safety and efficacy of albumin combined with endovascular therapy for participants with acute ischemic stroke is unknown. This randomized, double blinded, multicenter study was conducted in China and completed in 2025. Eligible participants were randomly assigned in a 1:1 ratio to albumin group (0.5 g/kg; maximum dose 150 mL; intravenously infusion once daily for 4 days) or placebo group (equivalent volume of placebo). The primary endpoint was the change in infarct volume from baseline to day 5. A total of 134 patients were randomized (66 in albumin group and 68 in placebo group) and 134 patients were included in the final analysis. Albumin reduced infarct volume growth from baseline to day 5 compared with placebo (median growth 7.5 mL vs 16.5 mL, adjusted median difference −8.63, 95%CI (−13.85 to −5.07); P = 0.003). The safety outcomes did not differ between the two groups. This work suggests that albumin plus endovascular therapy could significantly reduce infarct volume growth compared with the placebo group, without raising safety concerns. (Funded by the National Natural Science Foundation of China and others; ClinicalTrials.gov registration: NCT06538844.)
- 20 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessEfficacy and safety of albumin combined with endovascular therapy in the treatment of patients with acute ischemic stroke: a randomized clinical trial
The safety and efficacy of albumin combined with endovascular therapy for participants with acute ischemic stroke is unknown. This randomized, double blinded, multicenter study was conducted in China and completed in 2025. Eligible participants were randomly assigned in a 1:1 ratio to albumin group (0.5 g/kg; maximum dose 150 mL; intravenously infusion once daily for 4 days) or placebo group (equivalent volume of placebo). The primary endpoint was the change in infarct volume from baseline to day 5. A total of 134 patients were randomized (66 in albumin group and 68 in placebo group) and 134 patients were included in the final analysis. Albumin reduced infarct volume growth from baseline to day 5 compared with placebo (median growth 7.5 mL vs 16.5 mL, adjusted median difference −8.63, 95%CI (−13.85 to −5.07); P = 0.003). The safety outcomes did not differ between the two groups. This work suggests that albumin plus endovascular therapy could significantly reduce infarct volume growth compared with the placebo group, without raising safety concerns. (Funded by the National Natural Science Foundation of China and others; ClinicalTrials.gov registration: NCT06538844.)
- 22 October 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (1) , 162-164
Manipulation of glymphatic system by focused ultrasound: A promising treatment of neurological diseases
Glymphatic system is a vital waste clearance system in the brain which is associated with a variety of neurological disorders. Focused ultrasound combined with microbubbles (FUSMB) has been proven to enhance the clearance efficiency of the glymphatic system, and a recent study has uncovered the underlying mechanism. This study integrated two-photon imaging with focused ultrasound, revealing an enhanced cerebrospinal fluid (CSF) clearance resulting from significant deformation of cerebral vessels. This technology holds promising prospects for clinical application, yet further clinical translation and safety research still need to be completed.
- 22 October 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (1) , 162-164
Manipulation of glymphatic system by focused ultrasound: A promising treatment of neurological diseases
Glymphatic system is a vital waste clearance system in the brain which is associated with a variety of neurological disorders. Focused ultrasound combined with microbubbles (FUSMB) has been proven to enhance the clearance efficiency of the glymphatic system, and a recent study has uncovered the underlying mechanism. This study integrated two-photon imaging with focused ultrasound, revealing an enhanced cerebrospinal fluid (CSF) clearance resulting from significant deformation of cerebral vessels. This technology holds promising prospects for clinical application, yet further clinical translation and safety research still need to be completed.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10)
Maintaining Balance: An Update on Nonpharmacological Cytoprotection Therapy for Acute Ischemic Stroke
Reperfusion therapies have become the standard of care for patients with acute ischemic stroke (AIS). However, around half of treated patients do not regain functional independence despite successful recanalization. Potentially avoidable unbalanced states that prevail both before and after reperfusion therapy might account for such unfavorable functional outcomes. They include energy supply versus energy demand in the ischemia phase, hypoperfusion versus hyperperfusion in the reperfusion phase, and acute cytotoxic versus prorepair inflammation in subacute and chronic stages. Classical pharmacological approaches only target one of these imbalances, which is insufficient. Nonpharmacological therapies are typically multitargets and have provided new evidence for benefit in AIS. This topical review discusses the latest evidence regarding nonpharmacological strategies for brain cytoprotection in AIS targeting the 3 above imbalances. We also focus on the mechanisms underlying the benefits of nonpharmacological therapies and present promising results from recent large-scale clinical trials testing them in AIS. We further elaborate on the prospects of several nonpharmacological brain protection strategies applied in the different AIS scenarios. By gaining a deeper understanding of the imbalanced states in AIS and the advantages of nonpharmacological brain cytoprotection therapies, future clinical trials may be further refined to translate nonpharmacological brain cytoprotection therapies to the clinic.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10)
Maintaining Balance: An Update on Nonpharmacological Cytoprotection Therapy for Acute Ischemic Stroke
Reperfusion therapies have become the standard of care for patients with acute ischemic stroke (AIS). However, around half of treated patients do not regain functional independence despite successful recanalization. Potentially avoidable unbalanced states that prevail both before and after reperfusion therapy might account for such unfavorable functional outcomes. They include energy supply versus energy demand in the ischemia phase, hypoperfusion versus hyperperfusion in the reperfusion phase, and acute cytotoxic versus prorepair inflammation in subacute and chronic stages. Classical pharmacological approaches only target one of these imbalances, which is insufficient. Nonpharmacological therapies are typically multitargets and have provided new evidence for benefit in AIS. This topical review discusses the latest evidence regarding nonpharmacological strategies for brain cytoprotection in AIS targeting the 3 above imbalances. We also focus on the mechanisms underlying the benefits of nonpharmacological therapies and present promising results from recent large-scale clinical trials testing them in AIS. We further elaborate on the prospects of several nonpharmacological brain protection strategies applied in the different AIS scenarios. By gaining a deeper understanding of the imbalanced states in AIS and the advantages of nonpharmacological brain cytoprotection therapies, future clinical trials may be further refined to translate nonpharmacological brain cytoprotection therapies to the clinic.
- 30 May 2025
- Published by Springer Nature in Science China Life Sciences
- Vol. 68 (10) , 2867-2879
Therapeutic hypothermia for acute ischemic stroke: from preclinical studies to clinical trials
Therapeutic hypothermia (TH) is acknowledged as a promising neuroprotective strategy in clinical settings. However, its application in managing acute ischemic stroke (AIS) remains unclear due to variable clinical outcomes in bench and bedsides. A comprehensive review of original studies concerning hypothermia in ischemic stroke was conducted, sourcing data from PubMed, Web of Science, Embase, and Ovid Medicine databases covering the period from January 1, 1990 to October 31, 2023. Our search strategy yielded 1,218 articles from PubMed, 1,094 from Web of Science, 3,083 from Embase, and 2,841 from Ovid Medicine. After removing duplicates, review articles, meta-analyses, and in vitro studies focusing on hypoxic-ischemic encephalopathy or global cerebral ischemia, a total of 304 articles out of 5,669 papers were ultimately selected for in-depth analysis. Overall, we have found that there are significant differences in depth, duration, and delay between bench and bedside studies. We want to introduce the concepts of “actual brain temperature”, “hypothermia initiation time”, and “effective hypothermic duration” as crucial for the optimization of hypothermic therapy in AIS. We recommend critical parameters for the clinical translation of hypothermia, including a target temperature range of 34–35°C, a duration of 2–4 h, immediate initiation post-insult, and natural rewarming processes. We also advocate for selective brain cooling when reperfusion therapy is achieved. We find great differences in administrating TH for AIS between bench and bedsides. More efforts are still needed to enhance the likelihood of successful clinical translation and deepen the understanding of hypothermia’s role in AIS treatment.
- 30 May 2025
- Published by Springer Nature in Science China Life Sciences
- Vol. 68 (10) , 2867-2879
Therapeutic hypothermia for acute ischemic stroke: from preclinical studies to clinical trials
Therapeutic hypothermia (TH) is acknowledged as a promising neuroprotective strategy in clinical settings. However, its application in managing acute ischemic stroke (AIS) remains unclear due to variable clinical outcomes in bench and bedsides. A comprehensive review of original studies concerning hypothermia in ischemic stroke was conducted, sourcing data from PubMed, Web of Science, Embase, and Ovid Medicine databases covering the period from January 1, 1990 to October 31, 2023. Our search strategy yielded 1,218 articles from PubMed, 1,094 from Web of Science, 3,083 from Embase, and 2,841 from Ovid Medicine. After removing duplicates, review articles, meta-analyses, and in vitro studies focusing on hypoxic-ischemic encephalopathy or global cerebral ischemia, a total of 304 articles out of 5,669 papers were ultimately selected for in-depth analysis. Overall, we have found that there are significant differences in depth, duration, and delay between bench and bedside studies. We want to introduce the concepts of “actual brain temperature”, “hypothermia initiation time”, and “effective hypothermic duration” as crucial for the optimization of hypothermic therapy in AIS. We recommend critical parameters for the clinical translation of hypothermia, including a target temperature range of 34–35°C, a duration of 2–4 h, immediate initiation post-insult, and natural rewarming processes. We also advocate for selective brain cooling when reperfusion therapy is achieved. We find great differences in administrating TH for AIS between bench and bedsides. More efforts are still needed to enhance the likelihood of successful clinical translation and deepen the understanding of hypothermia’s role in AIS treatment.
- 15 May 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (2) , 333-349
Mitochondrial unfolded protein response (UPR mt ) as novel therapeutic targets for neurological disorders
Neurological disorders, including brain cancer, neurodegenerative diseases and ischemic/reperfusion injury, pose a significant threat to global human health. Due to the high metabolic demands of nerve cells, mitochondrial dysfunction is a critical feature of these disorders. The mitochondrial unfolded protein response (UPR mt ) is an evolutionarily conserved mitochondrial response, which is critical for maintaining mitochondrial and energetic homeostasis under stress. Previous studies have found that UPR mt participates in diverse physiological processes especially metabolism and immunity. Currently, increasing evidence suggest that targeted regulation of UPR mt can also effectively delay the progression of neurological diseases and improve patients’ prognosis. This review provides a comprehensive overview of UPR mt in the context of neurological diseases, with a particular emphasis on its regulatory functions. Additionally, we summarize the mechanistic insights into UPR mt in neurological disorders as investigated in preclinical studies, as well as its potential as a therapeutic target in the clinical management of neurological tumors. By highlighting the importance of UPR mt in the complex processes underlying neurological disorders, this review aims to bridge current knowledge gaps and inspire novel therapeutic strategies for these conditions.
- 15 May 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (2) , 333-349
Mitochondrial unfolded protein response (UPR mt ) as novel therapeutic targets for neurological disorders
Neurological disorders, including brain cancer, neurodegenerative diseases and ischemic/reperfusion injury, pose a significant threat to global human health. Due to the high metabolic demands of nerve cells, mitochondrial dysfunction is a critical feature of these disorders. The mitochondrial unfolded protein response (UPR mt ) is an evolutionarily conserved mitochondrial response, which is critical for maintaining mitochondrial and energetic homeostasis under stress. Previous studies have found that UPR mt participates in diverse physiological processes especially metabolism and immunity. Currently, increasing evidence suggest that targeted regulation of UPR mt can also effectively delay the progression of neurological diseases and improve patients’ prognosis. This review provides a comprehensive overview of UPR mt in the context of neurological diseases, with a particular emphasis on its regulatory functions. Additionally, we summarize the mechanistic insights into UPR mt in neurological disorders as investigated in preclinical studies, as well as its potential as a therapeutic target in the clinical management of neurological tumors. By highlighting the importance of UPR mt in the complex processes underlying neurological disorders, this review aims to bridge current knowledge gaps and inspire novel therapeutic strategies for these conditions.
- Open Access
- 24 March 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 22 (4) , e00579
Lipoprotein(a), remote ischemic conditioning, and stroke recurrence in patients with symptomatic intracranial atherosclerotic stenosis
- 24 March 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 22 (4) , e00579
Open AccessLipoprotein(a), remote ischemic conditioning, and stroke recurrence in patients with symptomatic intracranial atherosclerotic stenosis
- Open Access
- 1 January 2025
- Published by Aging and Disease in Aging and disease
Annexin A5 in Ischemic Stroke: Molecular Mechanisms and Translational Therapy Strategies
Previous research has identified externalized phosphatidylserine (PS) as an "eat me" signal in apoptosis regulation. Targeting PS thus represents a promising therapeutic approach. Annexin A5, known for its high affinity for PS, has traditionally been used as a FITC-labeled probe for detecting apoptosis. Recent studies have demonstrated that Annexin A5 can cross the blood-brain barrier and selectively bind to PS-exposed injured tissues, exerting multiple protective effects, such as anticoagulant, anti-inflammatory, and anti-apoptotic actions. Furthermore, emerging evidence suggests that Annexin A5 holds potential for molecular imaging of the ischemic penumbra and for the development of lesion-targeted drug delivery systems. In summary, Annexin A5 has garnered increasing attention for its neuroprotective properties and therapeutic potential. Ischemic stroke is one of the leading causes of disability and mortality worldwide. Ischemic stroke management still requires effective neuroprotective agents and innovative imaging strategies to improve clinical outcomes. This article provides a comprehensive analysis of protective mechanisms and translational applicability of Annexin A5 in ischemic stroke therapy, offering novel insights for the development of next-generation multi-target cerebrovascular interventions.
- 1 January 2025
- Published by Aging and Disease in Aging and disease
Open AccessAnnexin A5 in Ischemic Stroke: Molecular Mechanisms and Translational Therapy Strategies
Previous research has identified externalized phosphatidylserine (PS) as an "eat me" signal in apoptosis regulation. Targeting PS thus represents a promising therapeutic approach. Annexin A5, known for its high affinity for PS, has traditionally been used as a FITC-labeled probe for detecting apoptosis. Recent studies have demonstrated that Annexin A5 can cross the blood-brain barrier and selectively bind to PS-exposed injured tissues, exerting multiple protective effects, such as anticoagulant, anti-inflammatory, and anti-apoptotic actions. Furthermore, emerging evidence suggests that Annexin A5 holds potential for molecular imaging of the ischemic penumbra and for the development of lesion-targeted drug delivery systems. In summary, Annexin A5 has garnered increasing attention for its neuroprotective properties and therapeutic potential. Ischemic stroke is one of the leading causes of disability and mortality worldwide. Ischemic stroke management still requires effective neuroprotective agents and innovative imaging strategies to improve clinical outcomes. This article provides a comprehensive analysis of protective mechanisms and translational applicability of Annexin A5 in ischemic stroke therapy, offering novel insights for the development of next-generation multi-target cerebrovascular interventions.
- Open Access
- 23 October 2024
- Published by Springer Nature in Cell & Bioscience
- Vol. 14 (1) , 1-14
Revisiting Virchow’s triad: exploring the cellular and molecular alterations in cerebral venous congestion
Background: Cerebral venous thrombosis (CVT) is a rare but serious condition that can lead to significant morbidity and mortality. Virchow’s triad elucidates the role of blood hypercoagulability, blood flow dynamics, and endothelial damage in the pathogenesis of CVT. Cerebral venous congestion (CVC) increases the risk of cerebral venous sinus thrombosis and can lead to recurrent episodes and residual symptoms. However, the precise mechanism by which blood congestion leads to thrombosis remains unclear. Our objective was to investigate the cellular and molecular alterations linked to CVC through analysis of the pathological morphology of venous sinus endothelial cells and transcriptomic profiling. Results: This study demonstrated a remarkable correlation between CVC and the phenotypic transformation of endothelial cells from an anticoagulant to a procoagulant state. The findings revealed that cerebral venous stasis results in tortuous dilatation of the venous sinuses, with slow blood flow and elevated pressure in the sinuses and damaged endothelial cells of the retroglenoid and internal jugular vein ligation (JVL) rat model. Mechanistically, analysis of transcriptomic results of cerebral venous sinus endothelial cells showed significant activation of platelet activation, complement and coagulation cascades pathway in the JVL rats. Furthermore, the expression of von Willebrand factor (vWF) and coagulation factor VIII (F8) in the complement and coagulation cascades and Fgg and F2 in the platelet activation was increased in the cerebral venous sinuses of JVL rats than in sham rats, suggesting that endothelial cell injury in the venous sinus induced by CVC has a prothrombotic effect. In addition, endothelial cell damage accelerates coagulation and promotes platelet activation. Significantly, the concentrations of vWF, F2 and F8 in venous sinus blood of patients with internal jugular vein stenosis were higher than in their peripheral blood. Conclusion: Collectively, our data suggest that CVC can induce endothelial cell damage, which then exhibits a procoagulant phenotype and ultimately increases the risk of CVT. This research contributes to our understanding of the pathophysiology of CVC associated with procoagulant factors and reexamines the components of Virchow’s triad in the context of CVC.
- 23 October 2024
- Published by Springer Nature in Cell & Bioscience
- Vol. 14 (1) , 1-14
Open AccessRevisiting Virchow’s triad: exploring the cellular and molecular alterations in cerebral venous congestion
Background: Cerebral venous thrombosis (CVT) is a rare but serious condition that can lead to significant morbidity and mortality. Virchow’s triad elucidates the role of blood hypercoagulability, blood flow dynamics, and endothelial damage in the pathogenesis of CVT. Cerebral venous congestion (CVC) increases the risk of cerebral venous sinus thrombosis and can lead to recurrent episodes and residual symptoms. However, the precise mechanism by which blood congestion leads to thrombosis remains unclear. Our objective was to investigate the cellular and molecular alterations linked to CVC through analysis of the pathological morphology of venous sinus endothelial cells and transcriptomic profiling. Results: This study demonstrated a remarkable correlation between CVC and the phenotypic transformation of endothelial cells from an anticoagulant to a procoagulant state. The findings revealed that cerebral venous stasis results in tortuous dilatation of the venous sinuses, with slow blood flow and elevated pressure in the sinuses and damaged endothelial cells of the retroglenoid and internal jugular vein ligation (JVL) rat model. Mechanistically, analysis of transcriptomic results of cerebral venous sinus endothelial cells showed significant activation of platelet activation, complement and coagulation cascades pathway in the JVL rats. Furthermore, the expression of von Willebrand factor (vWF) and coagulation factor VIII (F8) in the complement and coagulation cascades and Fgg and F2 in the platelet activation was increased in the cerebral venous sinuses of JVL rats than in sham rats, suggesting that endothelial cell injury in the venous sinus induced by CVC has a prothrombotic effect. In addition, endothelial cell damage accelerates coagulation and promotes platelet activation. Significantly, the concentrations of vWF, F2 and F8 in venous sinus blood of patients with internal jugular vein stenosis were higher than in their peripheral blood. Conclusion: Collectively, our data suggest that CVC can induce endothelial cell damage, which then exhibits a procoagulant phenotype and ultimately increases the risk of CVT. This research contributes to our understanding of the pathophysiology of CVC associated with procoagulant factors and reexamines the components of Virchow’s triad in the context of CVC.
- Open Access
- 20 September 2024
- Published by Elsevier in Science Bulletin
- Vol. 69 (22) , 3618-3632
Blood-derived factors to brain communication in brain diseases
- 20 September 2024
- Published by Elsevier in Science Bulletin
- Vol. 69 (22) , 3618-3632
Open AccessBlood-derived factors to brain communication in brain diseases